

FARICIMAB solution for injection (Vabysmo® ▼) for diabetic macular oedema

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of FARICIMAB solution for injection (Vabysmo® ▼) for diabetic macular oedema.

GREY

Faricimab is indicated for the treatment of adults with visual impairment due to diabetic macular oedema (DMO).^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of DMO should continue to follow commissioned treatment pathways, national guidance and local formulary choices.

NICE have published positive technology appraisals for four therapies approved for the treatment of visual impairment due to DMO:

- > NICE TA274: [Ranibizumab for treating diabetic macular oedema](#) (27 February 2013)
- > NICE TA301: [Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy](#) (27 November 2013)
- > NICE TA346: [Aflibercept for treating diabetic macular oedema](#) (22 July 2015)
- > NICE TA349: [Dexamethasone intravitreal implant for treating diabetic macular oedema](#) (22 July 2015)

References

1. Roche Products Limited. Summary of Product Characteristics; [Vabysmo 120 mg/mL solution for injection](#), 16 May 2022. Accessed 21 June 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.